KR102654398B1 - Composition for preventing hair loss and cosmetics for preventing hair loss using the same - Google Patents
Composition for preventing hair loss and cosmetics for preventing hair loss using the same Download PDFInfo
- Publication number
- KR102654398B1 KR102654398B1 KR1020210036307A KR20210036307A KR102654398B1 KR 102654398 B1 KR102654398 B1 KR 102654398B1 KR 1020210036307 A KR1020210036307 A KR 1020210036307A KR 20210036307 A KR20210036307 A KR 20210036307A KR 102654398 B1 KR102654398 B1 KR 102654398B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair loss
- sulforaphane
- cosmetics
- preventing hair
- menthol
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 41
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 41
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 claims abstract description 88
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 claims abstract description 44
- 229960005559 sulforaphane Drugs 0.000 claims abstract description 44
- 235000015487 sulforaphane Nutrition 0.000 claims abstract description 44
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 30
- 201000004384 Alopecia Diseases 0.000 claims description 21
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 17
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 17
- 230000003676 hair loss Effects 0.000 claims description 16
- 208000024963 hair loss Diseases 0.000 claims description 16
- 235000004866 D-panthenol Nutrition 0.000 claims description 15
- 239000011703 D-panthenol Substances 0.000 claims description 15
- 235000020958 biotin Nutrition 0.000 claims description 15
- 239000011616 biotin Substances 0.000 claims description 15
- 229960002685 biotin Drugs 0.000 claims description 15
- 229960003949 dexpanthenol Drugs 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 10
- 210000004209 hair Anatomy 0.000 claims description 8
- -1 trideceth-10 Natural products 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 claims description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 claims description 4
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 claims description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 2
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 claims description 2
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 claims description 2
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 2
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 claims description 2
- 239000005792 Geraniol Substances 0.000 claims description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- GUUHFMWKWLOQMM-NTCAYCPXSA-N alpha-hexylcinnamaldehyde Chemical class CCCCCC\C(C=O)=C/C1=CC=CC=C1 GUUHFMWKWLOQMM-NTCAYCPXSA-N 0.000 claims description 2
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 claims description 2
- 229960001631 carbomer Drugs 0.000 claims description 2
- 239000004359 castor oil Substances 0.000 claims description 2
- 235000019438 castor oil Nutrition 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims description 2
- 235000000484 citronellol Nutrition 0.000 claims description 2
- 239000003205 fragrance Substances 0.000 claims description 2
- 229940113087 geraniol Drugs 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 2
- 229930007744 linalool Natural products 0.000 claims description 2
- 229940041616 menthol Drugs 0.000 claims description 2
- AEIJTFQOBWATKX-UHFFFAOYSA-N octane-1,2-diol Chemical compound CCCCCCC(O)CO AEIJTFQOBWATKX-UHFFFAOYSA-N 0.000 claims description 2
- 229940101267 panthenol Drugs 0.000 claims description 2
- 235000020957 pantothenol Nutrition 0.000 claims description 2
- 239000011619 pantothenol Substances 0.000 claims description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
- 239000008213 purified water Substances 0.000 claims description 2
- 229960004889 salicylic acid Drugs 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 229940045955 star anise extract Drugs 0.000 claims description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 2
- 229960000281 trometamol Drugs 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 27
- 238000012360 testing method Methods 0.000 description 22
- 238000011156 evaluation Methods 0.000 description 15
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 12
- 230000003656 anti-hair-loss Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000000007 visual effect Effects 0.000 description 9
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 229960003473 androstanolone Drugs 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 229940043810 zinc pyrithione Drugs 0.000 description 7
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 101150017399 DHRS9 gene Proteins 0.000 description 5
- 206010068168 androgenetic alopecia Diseases 0.000 description 5
- 201000002996 androgenic alopecia Diseases 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 102000001307 androgen receptors Human genes 0.000 description 4
- 108010080146 androgen receptors Proteins 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 108010003133 Aldo-Keto Reductase Family 1 Member C2 Proteins 0.000 description 3
- 102100024089 Aldo-keto reductase family 1 member C2 Human genes 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 210000003780 hair follicle Anatomy 0.000 description 2
- 108091008039 hormone receptors Proteins 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 238000012935 Averaging Methods 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 238000001135 Friedman test Methods 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000011869 Shapiro-Wilk test Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 230000006750 UV protection Effects 0.000 description 1
- 238000001793 Wilcoxon signed-rank test Methods 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229960003632 minoxidil Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Emergency Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품에 관한 것으로서 상세하게는 설포라판을 이용한 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품을 제시한다.The present invention relates to a composition for preventing hair loss and a cosmetic product for preventing hair loss using the same. In detail, it provides a composition for preventing hair loss using sulforaphane and a cosmetic product for preventing hair loss using the same.
Description
본 발명은 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품에 관한 것으로서, 상세하게는 설포라판을 이용한 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품과 관련된다.The present invention relates to a composition for preventing hair loss and cosmetics for preventing hair loss using the same. In particular , it relates to a composition for preventing hair loss using sulforaphane and cosmetics for preventing hair loss using the same.
현대 과학의 발달로 아름답고 젊은 피부를 원하는 사람들의 요구에 대응하여 다양한 화장품의 개발이 나날이 증가하고 있다. 관련 기업들은 기존의 화장품들보다 한층 업그레이드된 제품들을 개발하고 있으며, 또한 미용보다는 치료와 기능성에 초점을 맞춘 이른바 코스메슈티컬 화장품의 탄생에 기여하고 있다.With the development of modern science, the development of various cosmetics is increasing day by day in response to the needs of people who want beautiful and young skin. Related companies are developing products that are more upgraded than existing cosmetics, and are also contributing to the birth of so-called cosmeceutical cosmetics that focus on treatment and functionality rather than beauty.
국내에서는 코스메슈티컬 화장품 분야에 기존 화장품 기업뿐만 아니라 바이오, 제약 및 의료기기 기업의 진출이 확대되고 있다. 소비자들 역시 아름다움을 추구하는 미용 화장품뿐만 아니라, 치료와 기능성에 초점을 맞춘 새로운 개념의 화장품에 대한 관심이 증가되고 있는 추세이다.In Korea, not only existing cosmetics companies but also bio, pharmaceutical, and medical device companies are expanding into the cosmeceutical cosmetics field. Consumers are also showing increasing interest in not only beauty cosmetics that pursue beauty, but also new concept cosmetics that focus on treatment and functionality.
이러한 기능성 화장품으로서, 미백, 보습, 자외선 차단과 흡수, 유해산소 제거, 콜라겐 합성, 피부 주름 방지, 탈모 방지 등 다양한 효능을 가진 화장품들이 시판되고 있으며 이에 대한 관심도가 증대되고 있다.As such functional cosmetics, cosmetics with various effects such as whitening, moisturizing, UV protection and absorption, removal of harmful oxygen, collagen synthesis, skin wrinkle prevention, and hair loss prevention are being marketed, and interest in them is increasing.
이 중 탈모 방지와 관련하여 알려진 성분들이 있다. 예를 들면 대한민국 식약처 고시품목인 비오틴(Biotin), 덱스판테놀(Dexpanthenol), L-멘톨(L-Methol), 징크피리치온(Zinc Pyrithione)이 탈모 방지 성분으로서 이용되고 있고, 미국에서는 미국식품의약국(FDA)에서 피나스테라이드(피나스테리드, Finasteride)와 미녹시딜(Minoxidil)이 승인되어 있다.Among these, there are ingredients known to prevent hair loss. For example, Biotin, Dexpanthenol, L-Menthol, and Zinc Pyrithione, which are items notified by the Ministry of Food and Drug Safety in Korea, are used as hair loss prevention ingredients, and in the United States, American Food Finasteride and Minoxidil are approved by the Food and Drug Administration (FDA).
또한 그 외에 여러 가지 성분들이 탈모 방지가 가능하다고 알려져 있지만 이에 대한 효과 규명 및 안정성 검증은 이루어지지 않고 있다.In addition, various other ingredients are known to be able to prevent hair loss, but their effectiveness has not been identified or their safety has been verified.
본 발명은 항산화 효과를 가지는 것으로 알려진 설포라판(Sulforaphane)에 대하여 탈모 방지 효과가 우수한 것을 규명하여, 설포라판을 유효성분으로 포함하고 피부에 대한 부작용이 없으며 탈모 방지 효과가 우수한 탈모 방지용 조성물과 이를 이용하는 탈모 방지용 화장품을 제시한다.The present invention has investigated the excellent anti-hair loss effect of sulforaphane, which is known to have an antioxidant effect, and has developed a composition for preventing hair loss that contains sulforaphane as an active ingredient, has no side effects on the skin, and is excellent in preventing hair loss, and a composition for preventing hair loss using the same. Presents cosmetics.
그 외 본 발명의 세부적인 목적은 이하에 기재되는 구체적인 내용을 통하여 이 기술분야의 전문가나 연구자에게 자명하게 파악되고 이해될 것이다. Other detailed purposes of the present invention will be clearly understood and understood by experts or researchers in this technical field through the detailed contents described below.
위 과제를 해결하기 위하여 본 발명은 실시예로, 설포라판을 유효성분으로 포함하는 탈모 방지용 조성물 및 탈모 방지용 화장품을 제시한다.In order to solve the above problems, the present invention presents, as an example, a composition for preventing hair loss and a cosmetic for preventing hair loss containing sulforaphane as an active ingredient.
또한 설포라판을 유효성분으로 포함하는 탈모 예방 또는 치료용 약학적 조성물을 제시한다.In addition, a pharmaceutical composition for preventing or treating hair loss containing sulforaphane as an active ingredient is presented.
이 때 설포라판의 함량은 조성물 또는 화장품의 총량에 대하여 1μM 내지 25μM일 수 있다.At this time, the content of sulforaphane may be 1 μM to 25 μM based on the total amount of the composition or cosmetic.
한편, 상기 탈모 방지용 조성물과 탈모 방지용 화장품은 유효성분으로 비오틴, 덱스판테놀, L-멘톨로 이루어진 군에서 선택되는 적어도 하나의 성분을 더 포함할 수 있다.Meanwhile, the composition for preventing hair loss and cosmetics for preventing hair loss may further include at least one ingredient selected from the group consisting of biotin, dexpanthenol, and L-menthol as an active ingredient.
본 발명의 실시예에 따른 탈모 방지용 조성물과 탈모 방지용 화장품은, 피부에 대한 부작용이 없으며, 탈모 방지 효과가 우수하다. 또한 별도로 첨가되는 탈모 방지용 화장료를 줄일 수 있으므로, 제조 비용의 절감에도 기여할 수 있고 소비자 역시 경제적인 비용으로 제품을 사용할 수 있는 효과가 있다.The composition for preventing hair loss and the cosmetics for preventing hair loss according to an embodiment of the present invention have no side effects on the skin and are excellent in preventing hair loss. In addition, since it is possible to reduce the amount of separately added anti-hair loss cosmetics , it can contribute to reducing manufacturing costs and also allows consumers to use the product at an economical cost.
그 외 본 발명의 효과들은 이하에 기재되는 구체적인 내용을 통하여, 또는 본 발명을 실시하는 과정 중에 이 기술분야의 전문가나 연구자에게 자명하게 파악되고 이해될 것이다. Other effects of the present invention will be readily apparent and understood by experts or researchers in the technical field through the specific details described below or during the process of implementing the present invention.
도 1은 식약처 고시의 탈모방지 성분에 대하여 RAW 264.7 세포에 대한 농도에 따른 세포 독성을 실험한 결과를 나타내는 그래프.
도 2는 Hepa1c1c7 세포에 대하여 본 발명의 탈모 방지용 화장품 조성물의 유효성분인 설포라판의 농도에 따른 세포 독성을 측정하여 다른 탈모방지 성분의 세포 독성의 측정치와 비교한 결과를 나타낸 그래프.
도 3은 본 발명의 탈모 방지용 화장품 조성물의 유효성분인 설포라판과 다른 탈모방지 성분의 RT-PCR을 이용한 mRNA 발현 및 웨스턴 블롯 실험을 이용한 단백질 발현 수준 결과를 비교하여 나타낸 도면.
도 4는 본 발명의 탈모 방지용 화장품을 사용한 인체적용 임상시험에서 사용전과 사용후 6주 후의 피시험자들의 모발 상태를 비교하여 나타낸 도면.Figure 1 is a graph showing the results of testing the cytotoxicity of anti-hair loss ingredients in the Ministry of Food and Drug Safety notification according to concentration on RAW 264.7 cells.
Figure 2 for Hepa1c1c7 cells A graph showing the results of measuring cytotoxicity according to the concentration of sulforaphane, the active ingredient of the cosmetic composition for preventing hair loss of the present invention, and comparing it with the measured cytotoxicity of other anti-hair loss ingredients.
Figure 3 is a diagram showing a comparison of the results of mRNA expression using RT-PCR and protein expression levels using Western blot experiments of sulforaphane, the active ingredient of the cosmetic composition for preventing hair loss of the present invention, and other anti-hair loss ingredients.
Figure 4 is a diagram showing a comparison of the hair conditions of test subjects before use and 6 weeks after use in a human clinical trial using the cosmetics for preventing hair loss of the present invention.
상술한 본 발명의 특징 및 효과는 첨부된 도면과 관련한 다음의 상세한 설명을 통하여 보다 분명해 질 것이며, 그에 따라 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 본 발명의 기술적 사상을 용이하게 실시할 수 있을 것이다. 본 발명은 다양한 변경을 가할 수 있고 여러 가지 형태를 가질 수 있는 바, 특정 실시 예들을 도면에 예시하고 본문에 상세하게 설명하고자 한다. 그러나, 이는 본 발명을 특정한 개시형태에 대해 한정하려는 것이 아니며, 본 발명의 사상 및 기술범위에 포함되는 모든 변경, 균등물 내지 대체물을 포함하는 것으로 이해되어야 한다. 본 출원에서 사용한 용어는 단지 특정한 실시 예들을 설명하기 위해 사용된 것으로, 본 발명을 한정하려는 의도가 아니다.The features and effects of the present invention described above will become more apparent through the following detailed description in conjunction with the accompanying drawings, and accordingly, those skilled in the art will be able to easily implement the technical idea of the present invention. You will be able to. Since the present invention can be subject to various changes and can have various forms, specific embodiments will be illustrated in the drawings and described in detail in the text. However , this is not intended to limit the present invention to a specific disclosed form, and should be understood to include all changes, equivalents, and substitutes included in the spirit and technical scope of the present invention. The terms used in this application are only used to describe specific embodiments and are not intended to limit the invention.
이하, 본 발명의 일 실시예에 따른 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품에 대해 도면을 참조하여 상세하게 설명한다. 본 명세서에서는 서로 다른 실시예라도 동일유사한 구성에 대해서는 동일유사한 참조번호를 부여하고, 그 설명은 처음 설명으로 갈음한다.Hereinafter, a composition for preventing hair loss and cosmetics for preventing hair loss using the same according to an embodiment of the present invention will be described in detail with reference to the drawings. In this specification, similar reference numbers are assigned to identical and similar configurations even in different embodiments, and the description is replaced with the first description.
일반적으로 안드로겐 탈모증(AGA)은 남성과 여성의 연령에 따라 발생하는 탈모의 흔한 형태로 알려져 있다. 안드로겐 탈모증은 5α환원효소(5α-R)의 효소 활성에 의해 테스토스테론에서 방출되는 디하이드로테스토스테론(DHT, dihydrotestosterone)과 관련이 있다. 디하이드로테스토스테론은 두피의 모낭을 위축시키고 모낭이 가늘어지는 연모화를 유발하여 결국은 탈모로 이어지게 하는 작용을 한다.In general, androgenetic alopecia (AGA) is known to be a common form of hair loss that occurs with age in men and women. Androgenetic alopecia is related to dihydrotestosterone (DHT), which is released from testosterone by the enzymatic activity of 5α-reductase (5α-R). Dihydrotestosterone acts to atrophy the hair follicles on the scalp and cause thinning of the hair follicles, which ultimately leads to hair loss.
현재 테스토스테론이 DHT로 전환되는 것을 억제하는 5α환원효소의 억제제가 안드로겐 탈모증의 치료에 널리 사용되고 있다. 한편 이와는 다른 관점에서 DHT의 작용을 방해하여 탈모를 방지하는 방법을 고려할 수 있고 DHT의 분해 효소로서 AKR1C2 및 DHRS9가 알려져 있다. 이러한 효소가 발현되면 DHT가 안드로겐 수용체(AR)에 결합하여 호르몬 수용체 복합체를 형성하는 것을 방해하여 탈모 증상이 완화되도록 촉진하게 된다.Currently, inhibitors of 5α reductase, which inhibit the conversion of testosterone to DHT, are widely used in the treatment of androgenetic alopecia. Meanwhile, from a different perspective, a method of preventing hair loss by interfering with the action of DHT can be considered, and AKR1C2 and DHRS9 are known as enzymes that decompose DHT. When these enzymes are expressed, DHT binds to the androgen receptor (AR) and prevents the formation of a hormone receptor complex, thereby promoting relief of hair loss symptoms.
항산화 효능을 가지는 성분으로서 설포라판이 알려져 있다. 설포라판 성분이 암 줄기세포에 작용해 유방암을 치료 또는 예방할 수 있음은 이미 밝혀져 있다. 또한, 항산화는 피부 노화를 예방하고, 피부에 부정적인 영향을 주는 활성산소를 제거하여 피부를 더욱 건강하게 만드는 효과를 가지는 것으로 알려져 있다.Sulforaphane is known as an ingredient with antioxidant effects. It has already been shown that sulforaphane can treat or prevent breast cancer by acting on cancer stem cells. In addition, antioxidants are known to have the effect of preventing skin aging and making the skin healthier by removing free radicals that have a negative impact on the skin.
그러나, 항산화 효과를 나타내는 설포라판이 탈모 방지 기능도 포함하고 있는지에 관한 연구는 미진한 상태이다. 이에 본 발명에서는 설포라판의 탈모 방지 기능의 포함 가능성, 탈모 방지 기능의 정도 및 인체 적합성, 탈모 방지 기능을 위한 적정량에 대하여 규명하고, 이를 실제 화장품에 적용함으로써 설포라판을 유효성분으로 하는 탈모 방지용 조성물 및 이를 이용한 탈모 방지용 화장품을 제시한다.However, research on whether sulforaphane, which exhibits antioxidant effects, also has hair loss prevention functions is insufficient. Accordingly, in the present invention, the possibility of sulforaphane containing the hair loss prevention function, the degree and human compatibility of the hair loss prevention function, and the appropriate amount for the hair loss prevention function were investigated, and the results were applied to actual cosmetics to produce an anti-hair loss composition containing sulforaphane as an active ingredient and the same. We present cosmetics for preventing hair loss.
시약 및 세포의 준비Preparation of reagents and cells
본 발명의 대상인 설포라판과 고시된 탈모방지 물질인 비오틴, 덱스판테놀, L-멘톨, 징크피리치온 및 유기용매인 다이메틸설폭시화물(DMSO, Dimethyl sulfoxide)은 시그마 알드리치(Sigma Aldrich, USA)사로부터 구입하여 준비하였다.Sulforaphane, the subject of the present invention, biotin, dexpanthenol, L-menthol, zinc pyrithione, which are notified anti-hair loss substances, and dimethyl sulfoxide (DMSO), an organic solvent, are manufactured by Sigma Aldrich (USA). Purchased and prepared from.
또한 탈모 방지 기능을 확인하기 위한 Hepa1c1c7 세포와 세포 독성을 확인하기 위한 RAW 264.7 세포는 한국 세포주은행으로부터 구입하여 준비하였다.In addition, Hepa1c1c7 cells to check the anti-hair loss function and RAW 264.7 cells to check cytotoxicity were purchased and prepared from the Korean Cell Line Bank.
한편 세포 독성을 알아보기 위한 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliμM bromide(MTT)는 바이오맥스(Biomax, KOREA)사에서 구입하였다. Meanwhile, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliμM bromide (MTT) to determine cytotoxicity was purchased from Biomax (KOREA) .
세포배양cell culture
탈모 방지 기능을 확인하기 위한 Hepa1c1c7 세포는 10% FBS(Fetal Bovine SerμM)와 1% 페니실린/스트렙토마이신(Penicillin/Streptomycin)을 함유한 α-MEM(alpha MinimμM Essential MediμM Eagle) 용액에서 배양하였다.To confirm the anti-hair loss function, Hepa1c1c7 cells were cultured in α-MEM (alpha MinimμM Essential MediμM Eagle) solution containing 10% FBS (Fetal Bovine SerμM) and 1% Penicillin/Streptomycin.
한편 세포 독성을 확인하기 위한 RAW 264.7 세포는 10% FBS와 1% 페니실린/스트렙토마이신을 함유한 DMEM(Dulbecco's Modified Eagle's MediμM) 용액에서 배양하였다.Meanwhile, RAW 264.7 cells to check cytotoxicity were cultured in DMEM (Dulbecco's Modified Eagle's MediμM) solution containing 10% FBS and 1% penicillin/streptomycin.
상술한 Hepa1c1c7 세포와 RAW 264.7 세포의 배양은 37℃로 유지되는 5% CO₂배양기(CO₂Incubator)에서 이루어졌다.Cultivation of the above-described Hepa1c1c7 cells and RAW 264.7 cells was performed in a 5% CO₂ incubator maintained at 37°C.
설포라판과 탈모증상 완화 고시물질의 세포 독성 실험Cytotoxicity test of sulforaphane and substances notified to relieve hair loss symptoms
설포라판의 탈모 방지 효과를 평가하기 전에 탈모증상 완화 고시물질로 알려진 비오틴, 덱스판테놀, L-멘톨, 징크피리치온의 세포 독성을 확인하기 위하여 MTT Assay(Methyl Thiazolyl diphenyl TetrazoliμM Assay)를 사용하였다. 설포라판의 세포 독성에 대해서는 공개특허 10-2020-0041187호의 내용에 따라 RAW264.7 세포에 대해서는 생략하고 Hepa1c1c7 세포에 대해서만 실험하였다.Before evaluating the hair loss prevention effect of sulforaphane, MTT Assay (Methyl Thiazolyl diphenyl TetrazoliμM Assay) was used to check the cytotoxicity of biotin, dexpanthenol, L-menthol, and zinc pyrithione, which are known substances for alleviating hair loss symptoms. Regarding the cytotoxicity of sulforaphane, according to the contents of Patent Publication No. 10-2020-0041187, RAW264.7 cells were omitted and only Hepa1c1c7 cells were tested.
먼저 RAW264.7과 Hepa1c1c7 세포를 96홀 웰플레이트(Well Plate)에 웰당 1×10의 세포수로 분주하고 설포라판과 탈모증상 완화 고시물질의 시료를 농도별(1, 2.5, 5, 10 및 25μM)로 가한 후 24시간 동안 37℃의 온도로 CO₂배양기에서 배양하였다. 24시간 후 무혈청배양액(serμM free media)에 1/10의 MTT 용액을 섞어 100ul씩 분주하고 4시간 배양하였다. 그 후 마이크로리더(microplate reader, Biomax, KOREA)로 450nm에서 흡광도를 측정하였다. 동일한 조건으로 3회 반복하여 실험을 진행하였다.First, RAW264.7 and Hepa1c1c7 cells were distributed in a 96-hole well plate at a cell count of 1 After addition, it was cultured in a CO₂ incubator at a temperature of 37°C for 24 hours. After 24 hours, 1/10 MTT solution was mixed with serum-free culture medium (serμM free media), dispensed at 100 ul each, and cultured for 4 hours. Afterwards, the absorbance was measured at 450 nm using a microplate reader (Biomax, KOREA). The experiment was repeated three times under the same conditions.
그 결과 Raw264.7 세포에 대해서는 실험에 적용한 농도(1, 2.5, 5, 10 및 25μM)에서 설포라판, 비오틴, 덱스판테놀 및 L-멘톨은 세포 생존율이 93%~130%로서 큰 영향을 미치지 않았다. 그러나 징크피리치온은 세포 생존율이 70%~94 %로서 낮음을 확인하였다. 결론적으로, 설포라판, 비오틴, 덱스판테놀 및 L-멘톨은 모든 조건에서 대조군과 실험군 간의 세포 생존력에 유의한 차이가 없어 세포 독성에 대한 안정적인 조건임을 확인하였으나 징크피리치온의 경우 세포 생존력이 낮아 세포 독성에 대한 안정적이지 않은 조건임을 확인하였다(도 1 참조).As a result, for Raw264.7 cells, sulforaphane, biotin, dexpanthenol, and L-menthol did not have a significant effect on cell viability at the concentrations (1, 2.5, 5, 10, and 25 μM) applied in the experiment, with cell viability ranging from 93% to 130%. However, zinc pyrithione was confirmed to have a low cell survival rate of 70% to 94%. In conclusion, sulforaphane, biotin, dexpanthenol, and L-menthol showed no significant difference in cell viability between the control and experimental groups in all conditions, confirming that they were stable conditions for cytotoxicity, but zinc pyrithione had low cell viability and was cytotoxic. It was confirmed that the condition was not stable (see Figure 1).
한편 Hepa1c17 세포에 대해서는 실험에 적용한 농도(1, 2.5, 5, 10 및 25μM)에서 설포라판, 비오틴, 덱스판테놀 및 L-멘톨은 93%~110%의 세포 생존률을 나타내었다. 반면에 징크피리치온의 경우 94%~70%로 세포 생존률이 낮았다. 결론적으로, 설포라판, 비오틴, 덱스판테놀 및 L-멘톨은 모든 조건에서 대조군과 실험군 간의 세포 생존률에 유의한 차이가 없어 세포 독성에 대한 안정적인 조건임을 확인하였으나 징크피리치온의 경우 낮은 농도에서도 생존률이 낮게 나타남으로써 세포에 독성이 있음을 확인하였고 이에 따라 탈모 방지 기능을 규명하는 실험은 생략하였다(도 2 참조). Meanwhile, for Hepa1c17 cells, sulforaphane, biotin, dexpanthenol, and L-menthol showed cell survival rates of 93% to 110% at the concentrations applied in the experiment (1, 2.5, 5, 10, and 25 μM). On the other hand, in the case of zinc pyrithione, the cell survival rate was low at 94% to 70%. In conclusion, sulforaphane, biotin, dexpanthenol, and L-menthol showed no significant difference in cell survival rates between the control and experimental groups in all conditions, confirming that they were stable conditions for cytotoxicity. However, in the case of zinc pyrithione, the survival rate was low even at low concentrations. As a result, it was confirmed that it was toxic to cells, and accordingly, the experiment to determine the hair loss prevention function was omitted (see Figure 2).
위와 같이 1~25μM의 농도에서 설포라판, 비오틴, 덱스판테놀, L-멘톨은 세포독성이 나타나지 않아 안전할 것으로 예상된다. 특히 설포라판의 농도가 1μM 내지 20μM인 경우 세포 독성이 매우 낮아 무자극성임을 확인하였다.As above, at concentrations of 1 to 25 μM, sulforaphane, biotin, dexpanthenol, and L-menthol do not exhibit cytotoxicity and are expected to be safe. In particular, when the concentration of sulforaphane was 1 μM to 20 μM, cytotoxicity was very low and it was confirmed to be non-irritating.
한편 여기에서 시료를 균일하게 용해시키기 위해 세포독성에 영향을 주지 않는 유기용매인 0.1%의 DMSO를 사용하였다.Meanwhile, 0.1% DMSO, an organic solvent that does not affect cytotoxicity, was used to uniformly dissolve the sample.
설포라판의 탈모 억제 실험Hair loss inhibition experiment with sulforaphane
설포라판의 탈모 억제 유전자 발현을 확인하기 위하여 Hepa1c1c7 세포를 설포라판과 비오틴, 덱스판테놀 및 L-멘톨의 혼합물 농도에 따라 처리한 후 아래와 같이 RT-PCR과 웨스턴 블롯(Western Blot)을 수행하였다.To confirm the expression of genes suppressing hair loss by sulforaphane, Hepa1c1c7 cells were treated with different concentrations of a mixture of sulforaphane, biotin, dexpanthenol, and L-menthol, and then RT-PCR and Western Blot were performed as follows.
이때 설포라판은 단독으로 최종 농도 2.5, 5, 10, 20μM로 하여 Hepa1c1c7 세포에 투입하였고, 비오틴, 덱스판테놀, L-멘톨은 혼합물로 만들어서 최종 농도 2.5, 5, 10, 20μM로 하여 Hepa1c1c7 세포에 투입하였다.At this time, sulforaphane was individually injected into Hepa1c1c7 cells at final concentrations of 2.5, 5, 10, and 20 μM, and biotin, dexpanthenol, and L-menthol were mixed and injected into Hepa1c1c7 cells at final concentrations of 2.5, 5, 10, and 20 μM. .
1) RT-PCR(Reverse Transcription-Polymerase Chain Reaction)1) RT-PCR (Reverse Transcription-Polymerase Chain Reaction)
Hepa1c1c7 세포의 전체 RNA를 분리하였다(RNeasy Mini kit, Qiagen, Germany). 분리된 RNA는 수퍼스크립트 역전사 효소(Intron power cDNA synthesis kit, 인트론바이오테크놀러지사, Korea)와 올리고 dT 프라이머(oligo dT primer)를 이용하여 역전사하였다. RT-PCR은 제조업체의 지침에 따라 재조합 Taq DNA 중합 효소를 사용하여 수행되었다(2xPCR 마스터 믹스 솔루션, 인트론바이오테크놀러지사, Korea). GAPDH mRNA 수준은 대조군으로 사용되었다. 사용된 프라이머 서열은 아래의 표 1에 나타내었다.Total RNA from Hepa1c1c7 cells was isolated (RNeasy Mini kit, Qiagen, Germany). The isolated RNA was reverse transcribed using Superscript reverse transcriptase (Intron power cDNA synthesis kit, Intron Biotechnology, Korea) and oligo dT primer. RT-PCR was performed using recombinant Taq DNA polymerase according to the manufacturer's instructions (2xPCR Master Mix Solution, Intron Biotechnology, Korea). GAPDH mRNA level was used as control. The primer sequences used are shown in Table 1 below.
PCR 조건은 30초 동안 94℃ 변성, 30초 동안 60℃ 어닐링, 30초 동안 72℃ 연장의 30 사이클이었다. PCR 산물은 레드세이프(RedSafe) 염색용액(인트론바이오테크놀러지사, Korea)으로 염색한 2% 아가로스겔을 전기영동하여 분석하였다.PCR conditions were 30 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds, and extension at 72°C for 30 seconds. PCR products were analyzed by electrophoresis on a 2% agarose gel stained with RedSafe staining solution (Intron Biotechnology, Korea).
2) 웨스턴 블랏(Western blot)2) Western blot
Hepa1c1c7 세포의 세포 추출물을 도데실황산나트륨폴리아크릴아미드겔전기영동법(SodiμM Dodecyl Sulfate Polyacrylamide Gel Electrophoresis, SDS-PAGE)으로 분해하고, 폴리비닐리덴플루오라이드(PVDF) 막으로 옮기고, DHRS9 폴리클로날항체(DHRS9 Rabbit Polyclonal, MyBioSource, MBS768606), AKR1C2 폴리클로날항체(Invitrogen, PA5)로 면역 블롯팅한 후 항β액틴항체(Anti-beta Actin antibody, Ab8227, Abcam, Elgland)를 사용한 후 2차로 HRP항체(Goat Anti-Rabbit IgG H&L, Ab6721, Abcam, Elgland)와 함께 배양하였다. 반응성 밴드는 웨스턴라이팅 시약(clarityTM western ECL substrate, Bio Rad)을 사용하여 화학발광에 의해 검출되었다.Cell extracts from Hepa1c1c7 cells were resolved using Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE), transferred to polyvinylidene fluoride (PVDF) membrane, and incubated with DHRS9 polyclonal antibody (DHRS9). After immunoblotting with Rabbit Polyclonal, MyBioSource, MBS768606) and AKR1C2 polyclonal antibody (Invitrogen, PA5), anti-beta Actin antibody (Ab8227, Abcam, Elgland) was used, followed by secondary HRP antibody (Goat Anti-Rabbit IgG H&L, Ab6721, Abcam, Elgland). Reactive bands were detected by chemiluminescence using western writing reagent (clarity TM western ECL substrate, Bio Rad).
3) 실험결과3) Experiment results
먼저 설포라판에서 각 농도(2.5, 5, 10, 20μM)에 따라 PCR 산물(RNA수준)과 웨스턴 블롯(단백질 수준) 결과를 통해 Ak1c21과 Dhrs9의 유전자를 확인해 보았다.First, the genes of Ak1c21 and Dhrs9 were confirmed through PCR products (RNA level) and Western blot (protein level) results at each sulforaphane concentration (2.5, 5, 10, and 20 μM).
이때 설포라판의 농도가 증가될수록 RNA수준과 단백질수준에서 모두 Ak1c21의 유전자 수준이 증가됨을 확인하였다. 다만 Dhrs9의 경우 농도에 따라 RNA수준에서는 큰 차이가 나타나지 않았고, 단백질수준에서는 농도가 증가될수록 단백질 수준도 증가됨을 확인할 수 있었다(도 3a 참조).At this time, it was confirmed that as the concentration of sulforaphane increased, the gene level of Ak1c21 increased at both the RNA and protein levels. However, in the case of Dhrs9, there was no significant difference at the RNA level depending on the concentration, and at the protein level, it was confirmed that the protein level increased as the concentration increased (see Figure 3a).
특히 설포라판의 농도가 10μM 내지 20μM인 경우 RNA수준과 단백질수준에서 모두 우수한 Ak1c21과 Dhrs9의 유전자의 발현이 확인되었다.In particular, when the concentration of sulforaphane was 10 μM to 20 μM, excellent expression of Ak1c21 and Dhrs9 genes was confirmed at both RNA and protein levels.
한편 탈모증상 완화 고시물질로 알려진 비오틴(Biotin), 덱스판테놀 및 L-멘톨의 혼합물에 대하여 설포라판과 동일한 농도(2.5, 5, 10, 20μM)로 처리하여 확인해 보았다. 이때는 설포라판과 달리 RNA수준과 단백질수준에서 Ak1c21과 Dhrs9의 유전자 수준이 농도가 증가되어도 큰 차이가 나타나지 않음을 확인하였다(그림 3b).Meanwhile, a mixture of biotin, dexpanthenol, and L-menthol, which are known substances for alleviating hair loss symptoms, was treated and confirmed at the same concentration as sulforaphane (2.5, 5, 10, 20 μM). At this time, unlike sulforaphane, it was confirmed that there was no significant difference in the gene levels of Ak1c21 and Dhrs9 at the RNA and protein levels even when the concentration increased (Figure 3b).
이에 따라 설포라판은 DHT의 분해 효소인 AKR1C2 및 DHRS9의 수준을 증가시키는 것으로 확인되었고, 이러한 효소의 발현을 촉진하여 DHT가 안드로겐 수용체 (AR)에 결합하여 호르몬 수용체 복합체를 형성하는 것을 방해하여 탈모 증상이 완화되도록 촉진할 수 있을 것으로 예상할 수 있다.Accordingly, sulforaphane was confirmed to increase the levels of AKR1C2 and DHRS9, enzymes that decompose DHT, and promotes the expression of these enzymes, preventing DHT from binding to the androgen receptor (AR) to form a hormone receptor complex, leading to hair loss symptoms. It can be expected that this will promote relief.
비오틴, 덱스판테놀 및 L-멘톨의 경우 다른 작용을 통해 탈모 방지에 관여하는 것으로 생각되며 설포라판과 함께 사용할 경우 서로 다른 작용을 통해 상승 효과를 낼 수 있을 것으로 예상된다.Biotin, dexpanthenol, and L-menthol are thought to be involved in preventing hair loss through different actions, and are expected to produce a synergistic effect through different actions when used together with sulforaphane.
젤형 화장품의 제조Manufacturing of gel-type cosmetics
위와 같은 실험을 기초로 하여 설포라판을 포함하는 젤형 화장품을 제조하였다. 제조공정은 일반적인 젤형 화장품을 제조하는 공정을 채용하였다.Based on the above experiment, a gel-type cosmetic containing sulforaphane was manufactured. The manufacturing process adopted the process for manufacturing general gel-type cosmetics.
화장품의 성분으로는 설포라판을 포함하여 정제수, 에탄올, 글리세린, 피이지-60하이드로제네이티드캐스터오일, 트로메타민, 카보머, 트라이데세스-10, 멘톨, 향료, 살리실릭애씨드, 판테놀, 부틸렌글라이콜, 1,2-헥산 다이올, 카프릴릴글라이콜, 스타아니스추출물, 소듐하이알루로네이트, 제라니올, 리날룰, 시트로넬올, 헥실신남알, 나모넨이 사용되었다.Ingredients of cosmetics include sulforaphane, purified water, ethanol, glycerin, PEG-60 hydrogenated castor oil, tromethamine, carbomer, trideceth-10, menthol, fragrance, salicylic acid, panthenol, butylene glycol. Lycol, 1,2-hexane diol, caprylyl glycol, star anise extract, sodium hyaluronate, geraniol, linalool, citronellol, hexylcinnamal, and namonene were used.
상술한 설명에서는 젤형 화장품을 예로 들어 설명하였지만 적절한 양의 설포라판을 함유(1~25μM, 바람직하게는 10~20μM)하도록 하여 스킨, 로션, 파운데이션, 에센스, 크림, 팩, 폼 클렌징 등의 다른 화장품 군에도 적용이 가능할 것으로 예상된다.In the above description, gel-type cosmetics were used as an example, but by containing an appropriate amount of sulforaphane (1-25 μM, preferably 10-20 μM), other cosmetics such as skin, lotion, foundation, essence, cream, pack, and cleansing foam can be used. It is expected that it can also be applied.
또한 적절한 양의 설포라판을 함유(1~25μM, 바람직하게는 10~20μM)하도록 하여 탈모 예방 또는 치료용 약제을 제조하는 것도 가능할 것으로 예상된다.It is also expected that it will be possible to manufacture a drug for preventing or treating hair loss by containing an appropriate amount of sulforaphane (1 to 25 μM, preferably 10 to 20 μM).
본 발명의 젤형 화장품의 탈모 방지 효과를 검증하기 위하여 18~54세의 안드로겐성 탈모증으로 진단된 남녀 23명을 대상으로 하여 탈모 방지 효과를 검증하였다.In order to verify the hair loss prevention effect of the gel-type cosmetics of the present invention, the hair loss prevention effect was tested on 23 men and women diagnosed with androgenetic alopecia aged 18 to 54 years.
모든 측정 및 평가는 공기의 이동과 직사광선이 없으며 항온 항습조건(22±2℃, 50±5%)이 유지되는 공간에서 시험대상자가 피부 안정을 취한 상태에서 실시하였으며, 시험제품 사용전과 후에 평가를 실시하였다.All measurements and evaluations were conducted with the test subject's skin at rest in a space free of air movement and direct sunlight and maintained at constant temperature and humidity conditions (22±2°C, 50±5%), and evaluations were made before and after using the test product. It was carried out.
본 발명 젤형 화장품의 탈모 방지 효과 검증Verification of hair loss prevention effect of gel-type cosmetics of the present invention
1) 정수리 및 앞머리선 부위 육안 평가1) Visual evaluation of the crown and frontal hairline area
본 시험에서는 고해상도 디지털카메라(DSLR, Cannon Inc., Japan)를 이용하여 시험 제품 사용 전과 6주 사용 후에 동일한 조건, 구조 및 위치에서 정수리 부위(90도)와 앞머리선 부위(45도)를 사진 촬영하였다.In this test, a high-resolution digital camera (DSLR, Cannon Inc., Japan) was used to take pictures of the crown area (90 degrees) and frontal line area (45 degrees) under the same conditions, structure, and location before and after 6 weeks of use of the test product. did.
시험 제품 사용 전, 시험제품 6주 사용 후 0.000에서 0.609로 정수리 부위 육안 평가 점수가 증가하였다. 앞머리선 육안 평가 점수는 0.000에서 0.087로 나타나고 있다. 육안 평가 점수는 표 2에 따라 각 참가자들의 육안 평가를 진행한 후 이를 평균하여 산출되었다.Before using the test product, the visual evaluation score of the crown area increased from 0.000 to 0.609 after using the test product for 6 weeks. The visual evaluation score of the bangs ranges from 0.000 to 0.087. The visual evaluation score was calculated by averaging the visual evaluation of each participant according to Table 2.
그 결과 시험 제품 사용 전과 비교하여 시험제품 6주 사용 후 정수리 부위 육안 평가 점수(Score)가 유의하게 증가하였고, 앞머리선 부위의 육안 평가 점수(Score)는 유의한 변화가 없었다.(표 3).As a result, compared to before using the test product, the visual evaluation score (Score) of the crown area significantly increased after 6 weeks of use of the test product, and there was no significant change in the visual evaluation score (Score) of the frontal hairline area (Table 3).
2) 전체 모발 수 평가2) Total hair count assessment
폴리스코프(Folliscope, LeadM, Republic of Korea)는 두피 또는 모발을 확대 촬영하여 탈모 및 모발 성장 속도 등을 평가 할수 있는 장비이다.Folliscope (LeadM, Republic of Korea) is an equipment that can evaluate hair loss and hair growth speed by taking close-up images of the scalp or hair.
본 시험에서는 폴리스코프를 시험제품 사용 전과 6주 사용 후에 탈모 부위에 모발을 자른 후 직경 1mm의 작은점 문신을 하여 매번 문신을 중심으로 하여 포토트리코그램을 평가하였다(도 3).In this test, before using the test product and after using the test product for 6 weeks, hair was cut on the hair loss area, a small dot with a diameter of 1 mm was tattooed, and the phototricogram was evaluated with the tattoo as the center each time (Figure 3).
그 결과 전체 모발 수가 시험제품의 사용 전 및 사용 6주 후에 28.48에서 29.57로 증가하였다. 모발 수의 변화는 시험 제품군에서 제품 사용 후 증가하는 경향을 나타내었으며 사용 6주 후에서 통계적으로 유의성 있게 증가하였다(표 4).As a result, the total number of hairs increased from 28.48 to 29.57 before and 6 weeks after using the test product. The change in hair count tended to increase after using the product in the test product group, and the increase was statistically significant after 6 weeks of use (Table 4).
3) 통계 분석3) Statistical analysis
시험 제품 사용 전과 후의 통계적 유의성을 검증하기 위해 임베디드 온 SPSS 스태티스틱스26(Embedded on SPSS Statistics 26)를 이용하여 통계 분석하였으며, 95% 신뢰구간에서 유의확률 p<0.05일 때 유의성을 확인하였다.To verify statistical significance before and after using the test product, statistical analysis was performed using Embedded on SPSS Statistics 26, and significance was confirmed when the significance probability was p<0.05 in the 95% confidence interval.
기기평가를 통해 산출된 결과값은 연속형 변수로 평균과 표준편차를 구하여 표기하였으며, 설문평가 결과값은 범주형 변수로 빈도와 백분율로 표기하였다.The results calculated through the instrumental evaluation were expressed as continuous variables with the mean and standard deviation, and the survey evaluation results were expressed as frequencies and percentages as categorical variables.
데이터의 정규성은 샤피로 윌크 검정(Shapiro-wilk test)으로 검증하였으며, 측정 시점이 3회 이상인 반복 측정된 자료에서는 정규성을 만족할 경우 모수적 방법인 반복측정 분산분석(peated measures ANOVA)으로 검정한 후 본페로니 교정(Bonferroni correction)을 적용하여 사후 검정하였으며, 정규성을 만족하지 않을 경우 비모수적방법인 프리드만 검정(Friedman test)으로 검정한 후 본페로니 교정(Bonferroni correction)을 적용하여 윌콕슨부호서열검정(Wilcoxon signed rank test)으로 사후 검정하였다.The normality of the data was verified with the Shapiro-Wilk test, and in the case of data measured repeatedly with three or more measurement points, if normality was satisfied, the data were tested using repeated measures ANOVA, a parametric method. A post-test was performed by applying the Bonferroni correction, and if normality was not satisfied, it was tested using the Friedman test, a non-parametric method, and then the Wilcoxon signed sequence test was performed by applying the Bonferroni correction. A post hoc test was performed using (Wilcoxon signed rank test).
이와 같이 본 발명의 설포라판을 포함한 탈모 방지용 조성물 및 이를 포함하는 탈모 방지용 화장품은 설포라판을 유효성분으로 채택함으로써 적은 양으로도 탈모 방지 효과를 얻을 수 있고, 항산화효과까지 포함하므로 제조 경제적인 측면에서 유리하다.In this way, the anti-hair loss composition containing sulforaphane of the present invention and the anti-hair loss cosmetics containing the same can achieve a hair loss prevention effect even with a small amount by adopting sulforaphane as an active ingredient, and also contain an antioxidant effect, so they are advantageous in terms of manufacturing economy. .
앞서 설명한 본 발명의 상세한 설명에서는 본 발명의 바람직한 실시예를 참조하여 설명하였지만, 해당 기술분야의 숙련된 당업자 또는 해당 기술분야에 통상의 지식을 갖는 자라면 후술될 특허청구범위에 기재된 본 발명의 사상 및 기술 영역으로부터 벗어나지 않는 범위 내에서 본 발명을 다양하게 수정 및 변경시킬 수 있음을 이해할 수 있을 것이다.Although the detailed description of the present invention described above has been described with reference to preferred embodiments of the present invention, those skilled in the art or those skilled in the art will understand the spirit of the present invention as described in the patent claims to be described later. It will be understood that the present invention can be modified and changed in various ways without departing from the technical scope.
Claims (5)
설포라판, 정제수, 에탄올, 글리세린, 피이지-60하이드로제네이티드캐스터오일, 트로메타민, 카보머, 트라이데세스-10, 멘톨, 향료, 살리실릭애씨드, 판테놀, 부틸렌글라이콜, 1,2-헥산 다이올, 카프릴릴글라이콜, 스타아니스추출물, 소듐하이알루로네이트, 제라니올, 리날룰, 시트로넬올, 헥실신남알 및 나모넨을 포함하여 젤 형태로 구성되고,
상기 설포라판의 함량은 화장품의 총량에 대하여 10μM 내지 20μM이며,
유효성분으로 비오틴(Biotin), 덱스판테놀(Dexpanthenol), L-멘톨(L-menthol)의 혼합물을 더 포함하고,
비오틴, 덱스판테놀, L-멘톨의 혼합물의 함량은 화장품의 총량에 대하여 2.5μM 내지 5μM이며,
사용 6주 후의 모발의 수(N/cm2)가 3.8% 증가하는 것을 특징으로 하는
탈모 방지용 기능성 화장품.A functional cosmetic for preventing hair loss containing sulforaphane as an active ingredient,
Sulforaphane, purified water, ethanol, glycerin, PEG-60 hydrogenated castor oil, tromethamine, carbomer, trideceth-10, menthol, fragrance, salicylic acid, panthenol, butylene glycol, 1,2- It is composed of hexane diol, caprylyl glycol, star anise extract, sodium hyaluronate, geraniol, linalool, citronellol, hexylcinnamal, and namonene in a gel form,
The content of sulforaphane is 10 μM to 20 μM relative to the total amount of cosmetics,
It further contains a mixture of biotin, dexpanthenol, and L-menthol as active ingredients,
The content of the mixture of biotin, dexpanthenol, and L-menthol is 2.5 μM to 5 μM relative to the total amount of cosmetics,
Characterized by a 3.8% increase in the number of hairs (N/cm 2 ) after 6 weeks of use.
Functional cosmetics to prevent hair loss.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210036307A KR102654398B1 (en) | 2021-03-21 | 2021-03-21 | Composition for preventing hair loss and cosmetics for preventing hair loss using the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210036307A KR102654398B1 (en) | 2021-03-21 | 2021-03-21 | Composition for preventing hair loss and cosmetics for preventing hair loss using the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220131481A KR20220131481A (en) | 2022-09-28 |
| KR102654398B1 true KR102654398B1 (en) | 2024-04-03 |
Family
ID=83461072
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210036307A KR102654398B1 (en) | 2021-03-21 | 2021-03-21 | Composition for preventing hair loss and cosmetics for preventing hair loss using the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102654398B1 (en) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100801164B1 (en) | 2006-11-16 | 2008-02-05 | 김용인 | The compound for trichogenousness and preventing the depilation and cosmetic composition thereof |
| KR102115666B1 (en) | 2017-10-25 | 2020-05-27 | 연세대학교 산학협력단 | Composition comprising nonanal for preventing hair loss or stimulating hair growth |
-
2021
- 2021-03-21 KR KR1020210036307A patent/KR102654398B1/en active IP Right Grant
Non-Patent Citations (2)
| Title |
|---|
| Biochemical and Biophysical Research Communications, 2016, Vol. 472, pp.250-254. 1부.* |
| 식품의약품안전처 고시 "기능성화장품 기준 및 시험방법" 별표 9, 2018.12. 1부.* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220131481A (en) | 2022-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3821896A1 (en) | Composition for preventing hair loss or promoting hair regrowth | |
| CN116077369A (en) | Composition for removing wrinkles and plumping skin and preparation method and application thereof | |
| US9303261B2 (en) | Composition for controlling chromogenesis including microRNA | |
| KR102654398B1 (en) | Composition for preventing hair loss and cosmetics for preventing hair loss using the same | |
| JP2009298752A (en) | Skin care preparation composition for external use | |
| KR102023021B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
| KR101670865B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Sinomenine Hydrochloride | |
| KR102537521B1 (en) | Composition for preventing hair loss and promoting hair growth | |
| KR20230161776A (en) | Cosmetic composition containing Sancheoneo extract PDRN and cosmetics using the same | |
| KR101651248B1 (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Forsythin | |
| KR102074314B1 (en) | Composition for Preventing Hair Loss or Promoting Hair Growth | |
| KR20220137618A (en) | External composition for preventing hair loss and/or promoting hair growth | |
| US10125367B2 (en) | Composition for preventing or treating atopic dermatitis comprising X-shape DNA structure as active ingredient | |
| TWI331042B (en) | Anti-aging cosmetics comprising chemokine | |
| JP2021092534A (en) | Method for screening anti-aging component | |
| KR20160082113A (en) | Skin external composition for anti-anging comprising compound K and panaxydol | |
| KR20150085961A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Aloe-emodin | |
| JP2018052843A (en) | Hyaluronan synthase expression promoter, hyaluronan production promoter, and anti-skin aging composition containing the same | |
| KR20220161172A (en) | Composition for senomorphics or preventing skin aging | |
| JP6142342B2 (en) | Novel uses of Akinonogeshi extract | |
| KR20150085686A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing protopanaxadiol | |
| JP2018052842A (en) | Hyaluronan synthase expression promoter, hyaluronan production promoter, and anti-skin aging composition containing the same | |
| KR101984276B1 (en) | A body hair growth inhibition composition comprising berberine hydrochloride as an effective ingredient | |
| KR20200137491A (en) | Composition for reinforcing skin barrier | |
| KR20220162555A (en) | Composition for preventing hair loss and promoting hair growth comprising Gypsophila paniculata |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |